Atanasio
Pandiella Alonso
Universidad de Castilla-La Mancha
Ciudad Real, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Castilla-La Mancha (11)
2024
-
T-reg transcriptomic signatures identify response to check-point inhibitors
Scientific Reports, Vol. 14, Núm. 1
2023
-
Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications
Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257
2022
-
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
International Journal of Molecular Sciences, Vol. 23, Núm. 10
-
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology
Cancers, Vol. 14, Núm. 14
-
Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
Cancers, Vol. 14, Núm. 18
-
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
Therapeutic Advances in Medical Oncology, Vol. 14
2021
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
2020
-
An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy
Pharmaceutics, Vol. 12, Núm. 9, pp. 1-20
-
Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment
International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-21
2019
-
Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models
ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014
2007
-
An update into the pathophysiological role of HER2 in cancer: Therapeutic implications
Clinical and Translational Oncology